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Lung involvement is a well-recognized extra-articular mani- 
festation of ankylosing spondylitis (AS). Anecdotal reports 
suggest that the use of anti-TNF drugs may be related to lung 
disease and pulmonary fibrosis. To examine the association 
between anti-TNF drugs and the development of lung disease 
in patients with AS or psoriatic arthritis (PsA) we conducted 
a systematic review. Of the 670 papers identified by means 
of key word and hand search, only one full-text paper was 
considered potentially relevant but had to be discarded as 
it did not meet the eligibility criteria. Although no conclusion 
was reached, this is the first systematic review to examine this 
problem which is becoming increasingly important as these 
drugs are widely prescribed in patients with spondyloarthritis.
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ABSTRACT:
KEY WORDS:
l ung involvement is a well-recognized extra-articular mani- festation of ankylosing spondylitis (AS) [1], with a prevalence 
of 0–30%; the most frequent forms are upper lobe fibrosis, myce-
toma formation and pleural thickening [1,2]. However, high 
resolution computed tomography (HRTC) findings indicate that 
its prevalence is as high as 61% in patients with long-standing 
AS [2], but there are few data concerning patients with psoriatic 
arthritis (PsA) [3]. Anti-tumor necrosis factor (TNF) blockers 
have been successfully used to treat patients with moderate and 
severe AS or PsA [4], but anecdotal reports suggest that their 
use may be related to lung disease and pulmonary fibrosis [4]. 
The aim of this study was to examine the association between 
anti-TNF drugs and the development of lung disease in patients 
with AS or PsA.
The review’s protocol was registered with the international 
register of systematic reviews PROSPERO1 (http://www.crd.
PROSPERO Protocol registration No. CRD42014010367
york.ac.uk/PROSPERO/) and followed the PRISMA guidelines. 
In order to be included, studies had to be reviews or observa-
tional cross-sectional, non-interventional, case-control or 
cohort studies evaluating the risk of pulmonary complications 
in patients exposed to anti-TNF blockers. The systematic search 
of the MEDLINE and EMBASE databases, which was extended 
to grey literature sources, used the following keywords/MeSH 
terms: psoriatic arthritis, ankylosing spondylitis, spondyloar-
thritis, anti-TNF blockers, infliximab, etanercept, adalimumab, 
interstitial lung disease, lung fibrosis, and pulmonary fibrosis. 
The study participants had to have a diagnosis of AS or PsA 
based on classification criteria or a rheumatologist’s diagnosis; 
subjects with juvenile-onset AS or PsA were excluded. In order 
to be considered eligible, the papers had to report the prevalence 
of fibrosis or interstitial lung disease (ILD) in patients with AS 
or PsA treated with anti-TNF blockers.
The search covered a 34 year period (1 January 1980 to 30 
September 2014) and was conducted by two investigators (E.G. 
and F.A.) who independently selected the potentially eligible 
studies. Disagreements were resolved by consensus; if no agree-
ment could be reached a third investigator made the final deci-
sion. The data were individually extracted by F.A. and E.G. using 
a predefined extraction form. Figure 1 shows the study selection 
process. Of the 670 papers identified by means of the key word 
and hand search (189 from MEDLINE via PubMed, and 481 
from EMBASE excluding the MEDLINE results), 669 were 
excluded as being irrelevant to the research question on the basis 
of their titles and abstracts. One full-text paper was considered 
potentially relevant but had to be discarded as it did not meet 
the eligibility criteria. There were therefore no published obser-
vational studies assessing the risk of lung fibrosis and ILD in 
patients exposed to anti-TNF blockers, and no conclusion could 
be reached. Although no conclusion was reached, this is the first 
systematic review to examine the association between AS/PsA 
and ILD or lung fibrosis in patients treated with anti-TNF block-
ers, which is becoming increasingly important as these drugs 
are widely prescribed to improve symptoms and functional 
status in patients with spondyloarthritis (SpA). TNFα is a key 
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cytokine in the pathogenesis of ILD, playing a profibrotic role 
by up-regulation of pulmonary growth factor-beta 1 (TGFβ1) 
expression through extracellular regulated kinase-specific 
pathway activation in fibroblasts and regulation of p21 (cyclin-
dependent kinase inhibitor). Furthermore, it is a key regulator 
of the cell cycle, DNA repair and aptosis and antifibrotic effects 
by inhibiting fibroblast proliferation and limiting lung inflamma-
tion. Treatment with anti-TNF blockers may result in pulmonary 
shifts toward anti-inflammatory cytokines, contributing to profi-
brotic changes. These may induce the exacerbation or induction 
of ILD, which contributes to worst prognosis and quality of life 
in patients with SpA with or without lung involvement.
Furthermore, anti-TNF therapy is associated with increased 
risk of reactivation of latent tuberculosis (TB), although the 
current recommendations designed to prevent this are effective. 
Thus, due to the higher prevalence of ILD, clinicians must be 
aware of the non-specific ILDs revealed by HRCT in other-
wise asymptomatic SpA patients, which are undetectable by 
chest radiography and must not be confused with tuberculous 
lesions. Clearly, large controlled studies specifically designed 
to assess the pulmonary profile of anti-TNF blockers in clini-
cal practice in SpA patients with or without previous ILD are 
warranted. 
Correspondence 
Dr. F. Atzeni
Rheumatology Unit, L. Sacco University Hospital, Via G.B. Grassi 74, 20127 
Milano, Italy
Phone: (39-02) 3904-2489
Fax: (39-02) 3904-3454
email: atzenifabiola@hotmail.com
References
1. El Maghraoui A. Pleuropulmonary involvement in ankylosing spondylitis. Joint 
Bone Spine 2005; 72: 496-502.
2. El Maghraoui A, Dehhaoui M. Prevalence and characteristics of lung involvement 
on high resolution computed tomography in patients with ankylosing spondylitis: 
a systematic review. Pulm Med 2012; 2012: 965956
3. Peluso R, Iervolino S, Vitiello M, Bruner V, Lupoli G, Di Minno MN. Extra-articular 
manifestations in psoriatic arthritis patients. Clin Rheumatol 2015; 34 (4): 745-53.
4. Atzeni F, Boiardi L, Sallì S, Benucci M, Sarzi-Puttini P. Lung involvement and 
drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin 
Immunol 2013; 9: 649-57.
Figure 1. Study selection process
670 abstracts 
evaluated
669 records excluded 
(irrelevant to the 
research question) 
189 records 
identified in the 
MedLine database 
481 records 
identified in the 
EMBASE database 
No studies included 
in the qualitative and 
quantitative analysis
One full-text article excluded 
(no data concerning 
patients with AS/PsA)
One full-text 
article assessed 
for eligibility
Rift Valley Fever (RVF) is mosquito-borne virus that is endemic 
in parts of Africa. It primarily infects animals like sheep, cattle 
and goats and can have an economic impact on a community 
due to the loss of livestock. Last month, several federal health 
agencies including the NOAA, USDA and the CDC released 
a report concerning the risk of RVF outbreaks in East Africa 
due to El Niño. The NOAA says the current El Niño will likely 
peak during the Northern Hemisphere winter 2015–16 and end 
up being among the strongest El Niño episodes since 1950. 
According to the Emerging Health Risk Notification, El Niño 
and Rift Valley fever (RVF) risk, East Africa, published 3 weeks 
ago, the several federal agencies developed a RVF outbreak 
forecasting model that uses satellite-derived data, drawing 
on the tight coupling between RVF activity and El Niño-driven 
flooding, said it identified areas at risk for RVF activity because 
of substantially elevated rainfall in Sudan, South Sudan, Ethiopia, 
Somalia, Kenya, and Tanzania, noting that assistance is likely 
needed to minimize RVF impacts in East Africa. In addition to 
RVF effect on animals, humans can get infected through contact 
with infected animal blood or organs and through mosquito 
bites and the bites of blood-sucking flies. The agencies offer 
the following recommendations concerning preparation in East 
Africa: animal and human surveillance and health education, 
animal vaccination programs and vector control.
Posted by Robert Herriman on January 7, 2016 
http://outbreaknewstoday.com/rift-valley-fever-outbreaks-in-east-africa-
forecasted-with-el-nino-11587/
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Rift Valley fever outbreaks in East Africa forecasted with El niño
“It’s not whether you get knocked down, it’s whether you get up”
Vince Lombardi (1913-1970), American football player and coach
